Palisade Bio, Inc. (PALI) — SEC Filings
Palisade Bio, Inc. (PALI) — 50 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 24 8-K, 6 10-Q, 5 DEF 14A.
View Palisade Bio, Inc. on SEC EDGAR
Overview
Palisade Bio, Inc. (PALI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: Palisade Bio, Inc. filed an 8-K on April 2, 2026, reporting other events as of March 27, 2026. The filing does not contain specific financial details or significant business updates beyond the reporting of an event.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bearish, 43 neutral, 3 mixed. The dominant filing sentiment for Palisade Bio, Inc. is neutral.
Filing Type Overview
Palisade Bio, Inc. (PALI) has filed 24 8-K, 6 10-Q, 2 DEFA14A, 5 DEF 14A, 3 S-1, 2 10-K, 3 S-1/A, 1 SC 13G, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PALI's 42 recent filings, 5 were flagged as high-risk, 23 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$7.882M |
| EPS | -$1.38 |
| Debt-to-Equity | 1.17 |
| Cash Position | $5.227M |
| Operating Margin | N/A |
| Total Assets | $6.973M |
| Total Debt | $3.761M |
Key Executives
- Board of Directors
- Don Williams
- JD Finley
- Jeffrey C. Thacker
- Michael Nertney
- Donald Williams
- David J. Mazzo
- Robert L. Diamond
- Ryan J. Gunderson
- John E. Maciejewski
- Justin Grossman
- Matthew Bernstein
- Dr. Jonathan M. Frampton
- Dr. Robert E. Smith
- Dr. Jonathan M. Roth
Industry Context
Palisade Bio operates in the biotechnology sector, focusing on the development of novel therapeutics for inflammatory bowel disease (IBD). This is a highly competitive and capital-intensive industry characterized by long development cycles, significant regulatory hurdles, and the need for substantial ongoing investment in research and development. Success is often dependent on the efficacy and safety of a single drug candidate.
Top Tags
biotech (7) · corporate-governance (6) · Biotechnology (6) · financials (6) · corporate-action (4) · sec-filing (4) · 10-Q (4) · amendment (4) · Reverse Stock Split (3) · Corporate Governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months ended Sep 30, 2025) | $7.882M | Decreased from $11.094M in the prior year period |
| Research and Development Expenses (9 months ended Sep 30, 2025) | $4.019M | Decreased from $6.979M in the prior year period |
| Cash and Cash Equivalents (Sep 30, 2025) | $5.227M | Decreased from $9.821M at Dec 31, 2024 |
| Gross Proceeds from Equity Offering | $138M | Closed on October 2, 2025, significantly increasing working capital |
| Common Stock Shares Outstanding | 149,003,210 | As of November 5, 2025 |
| Basic and Diluted Net Loss Per Common Share (3 months ended Sep 30, 2025) | $0.38 | Improved from $2.32 in the prior year period |
| Common Stock Shares Issued and Outstanding (Sep 30, 2025) | 9,119,152 | Increased from 2,768,646 at Dec 31, 2024 |
| Total Stockholders' Equity (Sep 30, 2025) | $3,212 | Decreased from $7,492 at Dec 31, 2024, prior to the subsequent equity offering |
| Net Cash Used in Operating Activities (9 months ended Sep 30, 2025) | $7,703 | Decreased from $9,812 in the prior year period |
| Reverse Stock Split | 1-for-15 | Effected on April 5, 2024 |
| Shares underlying new warrants | 8,637,810 | Represents potential dilution if fully exercised |
| Current authorized common stock | 280,000,000 | Proposed to increase to 300,000,000 |
| Proposed authorized common stock | 300,000,000 | Increase from 280,000,000 |
| Common shares outstanding | 139,564,572 | As of Record Date October 17, 2025 |
| New warrant exercise price | $0.9047 | Per share exercise price for new warrants |
Forward-Looking Statements
- {"claim":"L1 Capital may have adjusted its stake in Palisade Bio, potentially increasing or decreasing its holdings.","entity":"L1 Capital Global Opportunities Master Fund, Ltd.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"The market might react to this updated institutional ownership, especially if the underlying change in shares owned is significant.","entity":"Palisade Bio, Inc.","targetDate":"February 2024","confidence":"low"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Palisade Bio, Inc. (PALI)?
Palisade Bio, Inc. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 24 8-K, 6 10-Q, 5 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PALI filings?
Across 50 filings, the sentiment breakdown is: 4 bearish, 43 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Palisade Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Palisade Bio, Inc. (PALI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Palisade Bio, Inc.?
Key financial highlights from Palisade Bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PALI?
The investment thesis for PALI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Palisade Bio, Inc.?
Key executives identified across Palisade Bio, Inc.'s filings include Board of Directors, Don Williams, JD Finley, Jeffrey C. Thacker, Michael Nertney and 11 others.
What are the main risk factors for Palisade Bio, Inc. stock?
Of PALI's 42 assessed filings, 5 were flagged high-risk, 23 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Palisade Bio, Inc.?
Recent forward-looking statements from Palisade Bio, Inc. include guidance on {"claim":"L1 Capital may have adjusted its stake in Palisade Bio, potentially increasing or decreasing its holdings.","e and 1 other predictions.